Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 10, 2009, Pages 2772-2776

  Ohwada, Jun ^a   Ozawa, Sawako ^a   Kohchi, Masami ^a   Fukuda, Hiroshi ^a   Murasaki, Chikako ^a   Suda, Hitomi ^a   Murata, Takeshi ^a   Niizuma, Satoshi ^a   Tsukazaki, Masao ^a   Ori, Kazutomo ^a   Yoshinari, Kiyoshi ^a   Itezono, Yoshiko ^a   Endo, Mika ^a   Ura, Masako ^a   Tanimura, Hiromi ^a   Miyazaki, Yoko ^a   Kawashima, Akira ^a   Nagao, Shunsuke ^a   Namba, Eitarou ^a   Ogawa, Koutarou ^a   Kobayashi, Kazuko ^a   Okabe, Hisafumi ^a   Umeda, Isao ^a   Shimma, Nobuo ^a   more..

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antitumor agent; BCRP; Camptothecin analog; Drug resistance; Prodrug; Topoisomerase I inhibitor; TP300; Water soluble

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAMPTOTHECIN DERIVATIVE; CH 0793076; IRINOTECAN; PRODRUG; TP 300; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TRANSFORMATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONKEY; MOUSE; NONHUMAN; PH; RAT; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DOGS; HAPLORHINI; HUMANS; HYDROGEN-ION CONCENTRATION; MICE; MICE, NUDE; PRODRUGS; RATS; TRANSPLANTATION, HETEROLOGOUS; WATER;

CANIS FAMILIARIS; RATTUS;

EID: 65349179115     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.03.123     Document Type: Article

References (14)

1. Kawato Y., Aonuma M., Hirota Y., Kuga H., and Sato K. Cancer Res. 51 (1991) 4187
2. Kingsbury W.D., Boehm J.C., Jakas D.R., Holden K.G., Hecht S.M., Gallagher G., Caranfa M.J., McCabe F.L., Faucette L.F., and Johnson R.K. J. Med. Chem. 34 (1991) 98
3. Mitsui I., Kumazawa E., Hirota Y., Aonuma M., Sugimori M., Ohsuki S., Uoto K., Ejima A., Terasawa H., and Sato K. Jpn. J. Cancer Res. 86 (1995) 776
4. Chabot G.G. Clin. Pharmacokinet. 33 (1997) 245
5. Hecht J.R. Oncology 12 (1998) 72
6. Dodds H.M., and Rivory L.P. Mol. Pharmacol. 56 (1999) 1346
7. Iyer L., King C.D., Whitington P.F., Green M.D., Roy S.K., Tephly T.R., Coffman B.L., and Ratain M.J. J. Clin. Invest. 101 (1998) 847
8. Ando Y., Saka H., Asai G., Sugiura S., Shimokata K., and Kamataki T. Ann. Oncol. 9 (1998) 845
9. Schellens J.H., Maliepaard M., Scheper R.J., Scheffer G.L., Jonker J.W., Smit J.W., Beijnen J.H., and Schinkel A.H. Ann. N.Y. Acad. Sci. 922 (2000) 188
10. Niizuma, S.; Tsukazaki, M.; Suda, H.; Murata, T.; Ohwada, J.; Ozawa, S.; Fukuda, H.; Murasaki, C.; Kohchi, M.; Morikami, K.; Yoshinari, K.; Endo, M.; Ura, M.; Tanimura, H.; Miyazaki, Y.; Takasuka, T.; Kawashima, A.; Namba, E.; Nakano, K,; Ogawa, K.; Kobayashi, K.; Okabe, H.; Umeda, I.; Shimma, N.; Bioorg. Med. Chem. Lett. 2009, 19, 2018.
11. Ishitsuka, H.; Okabe, H.; Umeda, I.; Tsukuda, T.; Shimma, N.; 2003, WO2003043631.
12. Englebretsen D.R., and Robillard G.T. Tetrahedron 55 (1999) 6623
13. +).
14. Endo, M.; Miwa, M.; Ura, M.; Tanimura, H.; Taniguchi, K.; Miyazaki, Y.; Ohwada, J.; Tsukazaki, M.; Niizuma, S.; Murata, T.; Ozawa, S.; Ogawa, K.; Nanba, E.; Nagao, S.; Shimma, N.; Yamada-Okabe, H.; Cancer Chemother. Pharmacol., submitted for publication.